<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00583622</url>
  </required_header>
  <id_info>
    <org_study_id>2007-0368</org_study_id>
    <nct_id>NCT00583622</nct_id>
  </id_info>
  <brief_title>Bevacizumab Plus Gemcitabine, Docetaxel, Melphalan, and Carboplatin in Ovarian Cancer Patients</brief_title>
  <official_title>Bevacizumab Combined With High-Dose Gemcitabine, Docetaxel, Melphalan, and Carboplatin in Patients With Advanced Epithelial Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to learn if bevacizumab, when given in&#xD;
      combination with gemcitabine, docetaxel, melphalan and carboplatin, or with topotecan,&#xD;
      cyclophosphamide and melphalan (if you are older than 60 or have an allergy to carboplatin),&#xD;
      can help to control ovarian cancer during a stem cell transplant. The safety of this drug&#xD;
      combination will also be studied.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Study Drugs:&#xD;
&#xD;
      Bevacizumab is designed to prevent or slow down the growth of cancer cells by blocking the&#xD;
      growth of blood vessels.&#xD;
&#xD;
      Carboplatin is designed to damage the DNA (the genetic material) of cancer cells, which may&#xD;
      cause them to die.&#xD;
&#xD;
      Melphalan is designed to damage the DNA of cells, which may cause cancer cells to die.&#xD;
&#xD;
      Docetaxel is designed to stop the growth of cancer cells, which may cause the cells to die.&#xD;
&#xD;
      Gemcitabine is designed to disrupt the growth of cancer cells, which may cause cancer cells&#xD;
      to die. It may also help docetaxel, carboplatin, and melphalan to be more effective by&#xD;
      stopping tumor cells from repairing damage caused by these drugs.&#xD;
&#xD;
      Topotecan is designed to damage the DNA of cells, which may cause cancer cells to die.&#xD;
&#xD;
      Cyclophosphamide is designed to damage the DNA of cells, which may cause cancer cells to die.&#xD;
&#xD;
      Stem Cell Removal:&#xD;
&#xD;
      Before you begin receiving the study drugs, you will have apheresis done to collect some of&#xD;
      your stem cells as a part of your standard of care. Apheresis is the process of removing part&#xD;
      of the blood (such as platelets or white blood cells) from the body in order to remove&#xD;
      certain elements, such as stem cells. Then, the rest of the blood is returned back to your&#xD;
      body.&#xD;
&#xD;
      Apheresis will be done through a central venous catheter (CVC), usually in the chest. A CVC&#xD;
      is a sterile flexible tube that will be placed into a large vein while you are under local&#xD;
      anesthesia. Your doctor will explain these procedures to you in more detail, and you will be&#xD;
      required to sign a separate consent form for each procedure.&#xD;
&#xD;
      Your stem cells will be put back in your body after you finish receiving gemcitabine,&#xD;
      docetaxel, melphalan, and carboplatin.&#xD;
&#xD;
      To prevent clotting, citrate (a blood thinner) will be added to the CVC during the apheresis&#xD;
      procedure.&#xD;
&#xD;
      Study Drug Administration:&#xD;
&#xD;
      If you are found to be eligible to take part in this study, 2 weeks before your admission to&#xD;
      the hospital (about 3 weeks before the stem cell transplant), you will receive bevacizumab&#xD;
      through a the CVC over 45 minutes.&#xD;
&#xD;
      On Day 1 of your stay in the hospital, you will receive bevacizumab through the CVC over 45&#xD;
      minutes.&#xD;
&#xD;
      As part of standard mouth care, you will be asked to do mouthwashes 4 times a day (for 2&#xD;
      minutes each time) with caphosol (artificial saliva) followed by glutamine. Fifteen (15)&#xD;
      minutes after each caphosol mouthwash, you will swish glutamine around in your mouth and&#xD;
      gargle for 2 minutes, then spit it out. Do not swallow it.&#xD;
&#xD;
      On Day 2, through the CVC, you will receive gemcitabine over 3 hours and docetaxel over 2&#xD;
      hours. If you are allergic to carboplatin or older than 60 you will receive topotecan over 30&#xD;
      minutes.&#xD;
&#xD;
      On Day 3-5, through the CVC, you will receive gemcitabine over 3 hours, melphalan over 15&#xD;
      minutes, and carboplatin over 2 hours.&#xD;
&#xD;
      On Day 6, you will not receive any study drugs.&#xD;
&#xD;
      On Day 7, you will receive the stem cells through the CVC over about 30-60 minutes.&#xD;
&#xD;
      Starting the day after your stem cell transplant, as part of standard care, you will receive&#xD;
      granulocyte-colony stimulating factor (G-CSF or filgrastim) as an injection under your skin&#xD;
      daily, starting 1 day after the transplant, until your blood cell levels return to normal.&#xD;
&#xD;
      Starting 2 days after your transplant until 10 days after your transplant, you will receive&#xD;
      methylprednisolone 2 times a day.&#xD;
&#xD;
      If you are allergic to carboplatin or older than 60:&#xD;
&#xD;
      On Day 1 of your stay in the hospital, you will receive bevacizumab through the CVC over 45&#xD;
      minutes.&#xD;
&#xD;
      On Day 2-4, through the CVC, you will receive cyclophosphamide over 2 hours and topotecan&#xD;
      over 30 minutes. Each time you receive cyclophosphamide, you will also receive mesna to&#xD;
      decrease the risk of bleeding in the bladder.&#xD;
&#xD;
      On Day 5-6, through the CVC, you will receive melphalan over 30 minutes and topotecan over 30&#xD;
      minutes.&#xD;
&#xD;
      On Day 7, you will not receive any study drugs.&#xD;
&#xD;
      On Day 8, you will receive the stem cells through the CVC over about 30-60 minutes.&#xD;
&#xD;
      Starting the day after your stem cell transplant, as part of standard care, you will receive&#xD;
      G-CSF (filgrastim) as an injection under your skin daily, starting 1 day after the&#xD;
      transplant, until your blood cell levels return to normal.&#xD;
&#xD;
      Study Visits:&#xD;
&#xD;
      At least once a week after the transplant, and then about 30, 60, and 100 days after your&#xD;
      stem cell transplant, the following tests and procedures will be performed:&#xD;
&#xD;
        -  Your medical history will be recorded.&#xD;
&#xD;
        -  You will have a physical exam.&#xD;
&#xD;
        -  You will be checked for possible reactions to the treatment, including graft-versus-host&#xD;
           disease (GVHD) and graft failure. Graft failure occurs when donor cells may not be able&#xD;
           to grow and multiply in your body. If this happens, there will be a high risk of&#xD;
           infections and/or bleeding.&#xD;
&#xD;
        -  Blood (about 3 tablespoons) will be drawn for routine tests and to check for tumor&#xD;
           markers to check the status of the disease.&#xD;
&#xD;
        -  Urine will be collected for routine tests.&#xD;
&#xD;
        -  You will have a pelvic exam, if your doctor thinks it is needed.&#xD;
&#xD;
        -  You will have an ECHO, if your doctor thinks it is needed.&#xD;
&#xD;
        -  You will have a lung function test, if your doctor thinks it is needed.&#xD;
&#xD;
        -  You will have CT scans of your chest, abdomen, and pelvis to check the status of the&#xD;
           disease, if your doctor thinks it is needed.&#xD;
&#xD;
        -  You will have a positron emission tomography - computed tomography (PET-CT) scan to&#xD;
           check the status of the disease. A PET-CT is CT scan taken after a small amount of&#xD;
           radioactive glucose (sugar) is injected into a vein to find cancer cells in the body.&#xD;
&#xD;
      These tests and procedures may be performed more often, if your doctor thinks it is needed.&#xD;
&#xD;
      End-of-Treatment Visit:&#xD;
&#xD;
      About 6 and 12 months after your stem cell transplant, then once a year after that (if your&#xD;
      doctor thinks it is needed), the study visit tests and procedures listed above will be&#xD;
      repeated.&#xD;
&#xD;
      Length of Study:&#xD;
&#xD;
      You will be off study after about 6 months. You will be taken off study early if the disease&#xD;
      gets worse, if not enough stem cells can be collected, or if you experience any intolerable&#xD;
      side effects.&#xD;
&#xD;
      Long-Term Follow-up:&#xD;
&#xD;
      If your doctor thinks it is necessary, you may have follow-up visits.&#xD;
&#xD;
      This is an investigational study. Bevacizumab is FDA approved and commercially available for&#xD;
      the treatment of colorectal cancer. Gemcitabine, docetaxel, melphalan, and carboplatin are&#xD;
      all FDA-approved and commercially available for the treatment of ovarian cancer. The use of&#xD;
      bevacizumab with gemcitabine, docetaxel, melphalan, and carboplatin is investigational.&#xD;
&#xD;
      Up to 30 patients will take part in this study. All will be enrolled at MD Anderson.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow Accrual&#xD;
  </why_stopped>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event-Free (EF) Rate</measure>
    <time_frame>Up to 6 Months</time_frame>
    <description>Percent of participants free of relapse or disease progression at end of 6 months. Event-free survival estimated from the first day of High-dose chemotherapy (day-6) until tumor progression, relapse, or death from any cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Participant Response</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Number of participants evaluated using Response to Treatment in Solid Tumors (RECIST) with definitions of Complete Response (CR): disappearance of all target lesions; and, Partial Response: at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter. Maintained Continued CR: participants who entered study in a CR and maintained CR post study treatment. Evaluations once a week till Day +30, then Days 30, 60, and 100 then at 6 months or until disease progression.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>Bevacizumab + High-Dose Chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bevacizumab 5 mg/kg by vein (IV) daily over 90 minutes for 2 Days + Carboplatin 333 mg/m^2 by vein over 2 hours for 3 Days + Docetaxel 300 mg/m^2 by vein over 2 hours for 1 Day + Gemcitabine 1,800 mg/m2 by vein over 3 hours for 4 Days + Melphalan 50 mg/m^2 by vein over 15 minutes for 3 Days + Stem Cell Transplant</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>5 mg/kg by vein daily over 90 minutes for 2 Days</description>
    <arm_group_label>Bevacizumab + High-Dose Chemotherapy</arm_group_label>
    <other_name>Avastin™</other_name>
    <other_name>Anti-VEGF monoclonal antibody</other_name>
    <other_name>rhuMAb-VEGF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>333 mg/m^2 by vein over 2 hours for 3 Days</description>
    <arm_group_label>Bevacizumab + High-Dose Chemotherapy</arm_group_label>
    <other_name>Paraplatin®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>300 mg/m^2 by vein over 2 hours for 1 Day</description>
    <arm_group_label>Bevacizumab + High-Dose Chemotherapy</arm_group_label>
    <other_name>Taxotere</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>1,800 mg/m2 by vein over 3 hours for 4 Days</description>
    <arm_group_label>Bevacizumab + High-Dose Chemotherapy</arm_group_label>
    <other_name>Gemzar®</other_name>
    <other_name>Gemcitabine Hyrdrochloride</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>50 mg/m^2 by vein over 15 minutes for 3 Days</description>
    <arm_group_label>Bevacizumab + High-Dose Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Stem Cell Transplant</intervention_name>
    <description>Stem Cell Removal via apheresis through a central venous catheter (CVC), usually in chest&#xD;
Stem Cell Replacement through CVC over about 30-60 minutes, Day 7 of treatment, following study drug regimen</description>
    <arm_group_label>Bevacizumab + High-Dose Chemotherapy</arm_group_label>
    <other_name>SCT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18 - &lt;70.&#xD;
&#xD;
          2. Patients with advanced ovarian, fallopian or primary peritoneal cancer in second or&#xD;
             later complete remission, or untreated or refractory relapse, defined as relapse&#xD;
             within 6 months of prior platinum treatment or lack of response to salvage treatment.&#xD;
&#xD;
          3. No evidence of small bowel obstruction, as determined by CT scan of the abdomen and&#xD;
             pelvis with oral and rectal contrast, within 30 days before the initiation of study&#xD;
             treatment.&#xD;
&#xD;
          4. Adequate renal glomerular and tubular function, as defined by estimated serum&#xD;
             creatinine clearance &gt;=60 ml/min, and urinary protein excretion &lt;=500 mg/day.&#xD;
&#xD;
          5. Adequate hepatic function, as defined by serum glutamic oxaloacetic transaminase&#xD;
             (SGOT), serum glutamic pyruvic transaminase (SGPT) &lt;=3 * upper limit of normal (ULN);&#xD;
             serum bilirubin and alkaline phosphatase &lt;=2 * ULN or considered not clinically&#xD;
             significant.&#xD;
&#xD;
          6. Adequate pulmonary function with Forced expiratory volume in one second (FEV1), forced&#xD;
             vital capacity (FVC) and Carbon Monoxide Diffusing Capacity (DLCO) &gt;=50% of predicted,&#xD;
             corrected for volume or hemoglobin.&#xD;
&#xD;
          7. Adequate cardiac function with left ventricular ejection fraction &gt;=45%. No&#xD;
             uncontrolled arrhythmias or symptomatic cardiac disease.&#xD;
&#xD;
          8. Zubrod performance status &lt;2.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Failure to collect more than 3 * 10e6 CD34+ stem cells/kg body weight&#xD;
&#xD;
          2. Patients with unresolved grade 3 or greater non-hematologic toxicity from previous&#xD;
             therapy. Patients with grade 2 toxicity will be eligible at the discretion of the&#xD;
             principal investigator.&#xD;
&#xD;
          3. Major surgery within 30 days before the initiation of study treatment&#xD;
&#xD;
          4. Radiotherapy within 21 days prior to initiation of study treatment&#xD;
&#xD;
          5. Patients with active Central Nervous System (CNS) disease.&#xD;
&#xD;
          6. Evidence of acute or chronic active hepatitis or cirrhosis. If positive hepatitis&#xD;
             serology, discuss with Principal Investigator and consider liver biopsy.&#xD;
&#xD;
          7. Uncontrolled infection, including HIV or HTLV-1 infection.&#xD;
&#xD;
          8. Aspirin (&gt; 325 mg/day) use within 10 days before initiation of study treatment.&#xD;
&#xD;
          9. Ongoing uncontrolled hypertension (&gt;140/90 mm Hg on medication).&#xD;
&#xD;
         10. Non-healing wound or significant traumatic injury within 30 days before the initiation&#xD;
             of study treatment&#xD;
&#xD;
         11. Previous autologous or allogeneic stem cell transplant during the past year.&#xD;
&#xD;
         12. Positive Beta HCG test in a woman with child-bearing potential, defined as not&#xD;
             post-menopausal for 12 months or no previous surgical sterilization.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yago Nieto, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>U.T.M.D. Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>MD Anderson Cancer Center website</description>
  </link>
  <verification_date>April 2013</verification_date>
  <study_first_submitted>December 20, 2007</study_first_submitted>
  <study_first_submitted_qc>December 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 31, 2007</study_first_posted>
  <results_first_submitted>February 26, 2013</results_first_submitted>
  <results_first_submitted_qc>April 10, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 21, 2013</results_first_posted>
  <last_update_submitted>April 10, 2013</last_update_submitted>
  <last_update_submitted_qc>April 10, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 21, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ovarian Cancer</keyword>
  <keyword>Epithelial Ovarian Cancer</keyword>
  <keyword>Bevacizumab</keyword>
  <keyword>Carboplatin</keyword>
  <keyword>Gemcitabine</keyword>
  <keyword>Docetaxel</keyword>
  <keyword>Melphalan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Melphalan</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Period: December 19, 2007 to January 11, 2012. All recruitment done at The University of Texas (UT) MD Anderson Cancer Center.</recruitment_details>
      <pre_assignment_details>One participant of the 13 enrolled did not receive treatment and was excluded from the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Bevacizumab + High-Dose Chemotherapy</title>
          <description>Bevacizumab 5 mg/kg by vein (IV) daily over 90 minutes for 2 Days + Carboplatin 333 mg/m^2 by vein over 2 hours for 3 Days + Docetaxel 300 mg/m^2 by vein over 2 hours for 1 Day + Gemcitabine 1,800 mg/m2 by vein over 3 hours for 4 Days + Melphalan 50 mg/m^2 by vein over 15 minutes for 3 Days + Stem Cell Transplant</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Bevacizumab + High-Dose Chemotherapy</title>
          <description>Bevacizumab 5 mg/kg by vein (IV) daily over 90 minutes for 2 Days + Carboplatin 333 mg/m^2 by vein over 2 hours for 3 Days + Docetaxel 300 mg/m^2 by vein over 2 hours for 1 Day + Gemcitabine 1,800 mg/m2 by vein over 3 hours for 4 Days + Melphalan 50 mg/m^2 by vein over 15 minutes for 3 Days + Stem Cell Transplant</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47" lower_limit="33" upper_limit="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Event-Free (EF) Rate</title>
        <description>Percent of participants free of relapse or disease progression at end of 6 months. Event-free survival estimated from the first day of High-dose chemotherapy (day-6) until tumor progression, relapse, or death from any cause.</description>
        <time_frame>Up to 6 Months</time_frame>
        <population>Due to the small number of patients treated, 12 out of 30 planned, an analysis was not possible.</population>
        <group_list>
          <group group_id="O1">
            <title>Bevacizumab + High-Dose Chemotherapy</title>
            <description>Bevacizumab 5 mg/kg by vein (IV) daily over 90 minutes for 2 Days + Carboplatin 333 mg/m^2 by vein over 2 hours for 3 Days + Docetaxel 300 mg/m^2 by vein over 2 hours for 1 Day + Gemcitabine 1,800 mg/m2 by vein over 3 hours for 4 Days + Melphalan 50 mg/m^2 by vein over 15 minutes for 3 Days + Stem Cell Transplant</description>
          </group>
        </group_list>
        <measure>
          <title>Event-Free (EF) Rate</title>
          <description>Percent of participants free of relapse or disease progression at end of 6 months. Event-free survival estimated from the first day of High-dose chemotherapy (day-6) until tumor progression, relapse, or death from any cause.</description>
          <population>Due to the small number of patients treated, 12 out of 30 planned, an analysis was not possible.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participant Response</title>
        <description>Number of participants evaluated using Response to Treatment in Solid Tumors (RECIST) with definitions of Complete Response (CR): disappearance of all target lesions; and, Partial Response: at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter. Maintained Continued CR: participants who entered study in a CR and maintained CR post study treatment. Evaluations once a week till Day +30, then Days 30, 60, and 100 then at 6 months or until disease progression.</description>
        <time_frame>Up to 6 months</time_frame>
        <population>One participant was not evaluable for response as participant expired prior to performing restaging evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Bevacizumab + High-Dose Chemotherapy</title>
            <description>Bevacizumab 5 mg/kg by vein (IV) daily over 90 minutes for 2 Days + Carboplatin 333 mg/m^2 by vein over 2 hours for 3 Days + Docetaxel 300 mg/m^2 by vein over 2 hours for 1 Day + Gemcitabine 1,800 mg/m2 by vein over 3 hours for 4 Days + Melphalan 50 mg/m^2 by vein over 15 minutes for 3 Days + Stem Cell Transplant</description>
          </group>
        </group_list>
        <measure>
          <title>Participant Response</title>
          <description>Number of participants evaluated using Response to Treatment in Solid Tumors (RECIST) with definitions of Complete Response (CR): disappearance of all target lesions; and, Partial Response: at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter. Maintained Continued CR: participants who entered study in a CR and maintained CR post study treatment. Evaluations once a week till Day +30, then Days 30, 60, and 100 then at 6 months or until disease progression.</description>
          <population>One participant was not evaluable for response as participant expired prior to performing restaging evaluation.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete Response (CR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Maintained Continued CR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial Response (PR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Evaluable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 years and six months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Bevacizumab + High-Dose Chemotherapy</title>
          <description>Bevacizumab 5 mg/kg by vein (IV) daily over 90 minutes for 2 Days + Carboplatin 333 mg/m^2 by vein over 2 hours for 3 Days + Docetaxel 300 mg/m^2 by vein over 2 hours for 1 Day + Gemcitabine 1,800 mg/m2 by vein over 3 hours for 4 Days + Melphalan 50 mg/m^2 by vein over 15 minutes for 3 Days + Stem Cell Transplant</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Mucositis</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated Bilirubin</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Enterococcus Infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Neutropenic Fever</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Elevated Creatinine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin Rash</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Yago Nieto, MD, PhD / Professor</name_or_title>
      <organization>The University of Texas MD Anderson Cancer</organization>
      <email>celsaenz@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

